Applied DNA Sciences, Inc. announced commercialization of Linea(TM) IVT Platform. The Linea IVT platform combines cell-free, enzymatically produced Linea? DNA IVT templates with its proprietary Linea?

RNAP to deliver multiple advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of dsRNA contamination resulting in higher target mRNA yields; and, 3) the delivery of IVT templates in as little as 14 days for milligram scale and 30 days for gram scale.